Science news

<<  return



Hormonal Therapy May Be OK for Women Receiving Anticoagulants

Women who receive therapeutic anticoagulation and hormonal therapy are not an increased risk for recurrent venous thromboembolism (VTE) relative to women who receive therapeutic anticoagulation and no hormonal therapy, according to an analysis of the EINSTEIN deep vein thrombosis and pulmonary embolism cohorts published online December 23 in Blood.

The incidence of VTE was 3.7% per year "on" hormonal therapy and 4.7% per year "off" hormonal therapy, with an adjusted hazard ratio of 0.56 (95% confidence interval, 0.23 - 1.39). The upper limit of the 95% confidence interval around the hazard ratio excluded a clinically important difference in recurrent VTE.

The EINSTEIN deep vein thrombosis and pulmonary embolism studies used an open-label design. The women in the study were younger than 60 years (n = 1888) and were receiving anticoagulation with either rivaroxaban or enoxaparin/vitamin K antagonist.